MannKind Corporation (MNKD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Mankind Corporation First Quarter 2026 Financial Results Earnings Call. As a reminder, this call is being recorded on May 6th, 2026 and will be available for replay on the Mankind Corporation website shortly after this call for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see the Form 10Q for the period ended March 31st, 2026, the earnings release, and the slides prepared for this presentation. Joining us today from Mankind, our Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Chris Prentice. I'd now like to turn the conference over to Mr. Castagna. Please go ahead, sir. Thanks, Operator. Good afternoon, everyone. Thank you for joining us for our Q1 2026 earnings call. Here's today's agenda, and I'll start with some opening remarks. In the first quarter, we continue to execute our strategy to evolve mankind to a diversified company positioned to deliver sustained long-term growth. The company is fundamentally different than it was even a few years ago, and we are excited about the near-term milestones that will further advance the company's evolution. Today, we will discuss the recent positive developments with United Therapeutics and articulate our growth plans that we expect will drive significant shareholder value over the coming years. Let's begin with our announcement earlier today that Mankind 1501 has been unveiled as Relenopeg DPI, which United Therapeutics optioned into back in August last year. Our formulation team has been moving Relenopeg DPI forward expeditiously, ...